– NETHERLANDS, Amsterdam – VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the appointment of Khurem Farooq to its Board as an independent director, effective immediately.
“We are delighted to welcome Khurem to VectorY as an independent board member. He brings a wealth of leadership experience across operations, strategy and drug development in the pharma and biotech industry, which will be invaluable as we move into the next stage of growth of our company and advance our lead program VTx-002 for the treatment of Amyotrophic Lateral Sclerosis towards clinical development,” said CEO, Sander van Deventer.
About Khurem Farooq
Khurem Farooq is an accomplished industry leader who brings more than 20 years of operational and drug development experience. He currently serves as the CEO at Aiolos Bio which recently announced an agreement to be acquired by GSK. Previously Khurem served as the CEO of Gyroscope, which was acquired by Novartis in 2021. Before Gyroscope, Khurem was SVP of the Immunology and Ophthalmology business unit at Genentech, part of the Roche Group, where he led the commercialization and launch planning of several medicines and contributed to the development of several pipeline products. Khurem holds a Master’s Degree in Business Administration as well as an Honours degree in Biological Sciences.
Khurem Farooq commented: “I am excited to join this talented team at such a pivotal time. I am very impressed with VectorY’s unique capabilities to combine gene and antibody therapy drug development as well as its pipeline progress. The company’s innovative approach has the potential to overcome limitations of current therapies and translate into disease-modifying treatments across multiple neurodegenerative diseases, including ALS.”
About VectorY
VectorY is on a mission to provide patients with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases such as ALS and Huntington’s disease.
SOURCE: https://www.vectorytx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
